Tilpotide, the strongest weight-loss drug, has a unique activity to stimulate insulin secretion
Tirzepatide is a diabetes treatment developed by Eli Lilly and Company. It is a dual agonist of glucose-dependent insulin-stimulating polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. Activating the GLP-1 receptor reduces hunger and thus diet and caloric intake, while activating the GIP receptor reduces diet and caloric intake and